Herein, we show the safety and efficacy of targeting tumor vasculature-associated endothelial and tumor cell-expressed CD105 by an Lm-based vaccine, Lm-LLO-CD105A, in both subcutaneous and orthotopic models of RCC. The gene discussed is ENG; the disease is neoplasm.